Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
February 21, 2023 07:22 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
January 24, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone WEST CHESTER, Pa., Jan. 24, 2023 ...
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
January 04, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
Registration Stability Batch for VP-102 Completed and Placed on Stability Process Validation Batches Successfully Manufactured Verrica Reaffirms its Expected Q1 2023 NDA Resubmission for VP-102 ...
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 07, 2022 16:05 ET
|
Verrica Pharmaceuticals Inc.
Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, Pa.,...
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2022 16:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 11, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun...
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
August 01, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
The Company earns $8 Million Phase 3 Milestone Payment WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica Announces Pricing of Public Offering of Common Stock
June 29, 2022 21:23 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Proposed Public Offering of Common Stock
June 29, 2022 16:01 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
June 28, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...